ERBB2 and breast carcinoma: Treatment with tamoxifen failed to cause any significant reduction in MCF-7/HER2-18 tumors growing in the presence of estrogen, thereby confirming that HER2 overexpression suffices to drive tamoxifen resistance in ER-positive MCF-7/HER2-18 breast cancer cells in vivo [11].